AC Immune Statistics
Total Valuation
AC Immune has a market cap or net worth of $161.28 million. The enterprise value is $2.40 million.
Important Dates
The last earnings date was Wednesday, April 30, 2025, before market open.
| Earnings Date | Apr 30, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
AC Immune has 98.94 million shares outstanding. The number of shares has increased by 12.76% in one year.
| Current Share Class | 98.94M |
| Shares Outstanding | 98.94M |
| Shares Change (YoY) | +12.76% |
| Shares Change (QoQ) | +0.42% |
| Owned by Insiders (%) | 3.60% |
| Owned by Institutions (%) | 7.17% |
| Float | 39.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.09 |
| Forward PS | n/a |
| PB Ratio | 1.53 |
| P/TBV Ratio | 3.21 |
| P/FCF Ratio | 3.01 |
| P/OCF Ratio | 3.10 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.07 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 0.04 |
Financial Position
The company has a current ratio of 1.53, with a Debt / Equity ratio of 0.05.
| Current Ratio | 1.53 |
| Quick Ratio | 1.50 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | 0.11 |
| Interest Coverage | -342.25 |
Financial Efficiency
Return on equity (ROE) is -43.50% and return on invested capital (ROIC) is -26.05%.
| Return on Equity (ROE) | -43.50% |
| Return on Assets (ROA) | -17.07% |
| Return on Invested Capital (ROIC) | -26.05% |
| Return on Capital Employed (ROCE) | -46.21% |
| Revenue Per Employee | $186,129 |
| Profits Per Employee | -$342,563 |
| Employee Count | 172 |
| Asset Turnover | 0.15 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, AC Immune has paid $3,394 in taxes.
| Income Tax | 3,394 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.44% in the last 52 weeks. The beta is 1.62, so AC Immune's price volatility has been higher than the market average.
| Beta (5Y) | 1.62 |
| 52-Week Price Change | -29.44% |
| 50-Day Moving Average | 1.87 |
| 200-Day Moving Average | 2.80 |
| Relative Strength Index (RSI) | 42.79 |
| Average Volume (20 Days) | 135,667 |
Short Selling Information
| Short Interest | 1.38M |
| Short Previous Month | 1.45M |
| Short % of Shares Out | 2.90% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 7.50 |
Income Statement
In the last 12 months, AC Immune had revenue of $32.01 million and -$58.92 million in losses. Loss per share was -$0.59.
| Revenue | 32.01M |
| Gross Profit | -39.62M |
| Operating Income | -58.46M |
| Pretax Income | -69.76M |
| Net Income | -58.92M |
| EBITDA | -56.82M |
| EBIT | -58.46M |
| Loss Per Share | -$0.59 |
Full Income StatementBalance Sheet
The company has $164.73 million in cash and $5.85 million in debt, giving a net cash position of $158.88 million or $1.61 per share.
| Cash & Cash Equivalents | 164.73M |
| Total Debt | 5.85M |
| Net Cash | 158.88M |
| Net Cash Per Share | $1.61 |
| Equity (Book Value) | 107.24M |
| Book Value Per Share | 1.07 |
| Working Capital | 59.83M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $52.04 million and capital expenditures -$779,456, giving a free cash flow of $53.63 million.
| Operating Cash Flow | 52.04M |
| Capital Expenditures | -779,456 |
| Free Cash Flow | 53.63M |
| FCF Per Share | $0.54 |
Full Cash Flow StatementMargins
Gross margin is -123.76%, with operating and profit margins of -182.62% and -184.05%.
| Gross Margin | -123.76% |
| Operating Margin | -182.62% |
| Pretax Margin | -184.03% |
| Profit Margin | -184.05% |
| EBITDA Margin | -177.47% |
| EBIT Margin | -182.62% |
| FCF Margin | 167.52% |
Dividends & Yields
AC Immune does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.76% |
| Shareholder Yield | -12.76% |
| Earnings Yield | -36.53% |
| FCF Yield | 33.25% |
Analyst Forecast
The average price target for AC Immune is $10.00, which is 513.50% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.00 |
| Price Target Difference | 513.50% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 58.18% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AC Immune has an Altman Z-Score of -1.55 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.55 |
| Piotroski F-Score | 4 |